Business Wire

MN-TENNANT-COMPANY

22.2.2024 14:46:26 CET | Business Wire | Press release

Share
Tennant Company and Brain Corp Sign Exclusive Technology Agreement To Accelerate Robotic Floor Cleaning Innovation and Adoption

Tennant Company (NYSE: TNC), a world leader in the design, manufacturing, and marketing of solutions to reinvent how the world cleans, and Brain Corp, a leading autonomous technology company creating transformative solutions in robotics and artificial intelligence (“AI”), jointly announce an exclusive technology agreement to accelerate the development and adoption of the next generation of robots in the floor-cleaning industry. This landmark agreement builds on the historically successful partnership between the two companies and seeks to accelerate innovation. Tennant and Brain Corp bring complementary strengths to the relationship that create an exceptional customer support ecosystem. Tennant has a 150-plus year history of building industry-leading cleaning equipment and has expansive direct sales and service coverage. Brain Corp offers industry-leading and AI-enabled AMR cleaning technology, with more than 6,500 Tennant cleaning robots in the field powered by Brain. We expect Tennant’s purpose-built robotic equipment driven by Brain Corp’s next-generation and AI-enabled autonomous navigation technology will improve the customer return on investment and enable more customers to invest in robotic cleaning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222888342/en/

“Our customers have always relied on Tennant for equipment innovation and aftermarket support to address key business challenges such as labor shortages and cost pressures,” said Tennant Company President and CEO Dave Huml. “Our partnership with Brain Corp has already produced an industry-leading portfolio of autonomous equipment in this fast-growing space. We are excited to expand our existing partnership to dramatically accelerate the transition to robotic cleaning and drive adoption in new segments of our markets. By combining cleaning intelligence and automation, we are poised to lead the disruption that AI-enabled robotic technology will bring to our industry.”

In the second quarter of 2024, Tennant will launch the new X4 ROVR, the company’s first purpose-built Autonomous Mobile Robot (AMR). The X4 ROVR offers greater maneuverability, is specifically designed for operation in smaller spaces, and is driven by Brain Corp’s next-generation navigation software and hardware suite which will be available exclusively on Tennant machines for floorcare applications. Its compact size, improved obstacle detection, and enhanced mobility will result in fewer assists and deliver a step-change improvement in customer ROI. The X4 ROVR is expected to drive an increase in robotic cleaning adoption as it provides an on-ramp to customers for whom robotic technology has previously been out of reach. The X4 ROVR is the first of many planned future AMR cleaning products powered by Brain Corp’s next-generation technology that will be exclusively available on Tennant equipment. With this agreement, the partnership seeks to accelerate the build-out of a portfolio of robotic floor-cleaning solutions to cover more cleaning applications and enhance customers’ return on investment to drive adoption.

Tennant and Brain Corp bring complementary strengths to the partnership that are positioned to drive an acceleration of robotic cleaning adoption. Tennant has a 150-plus year history of building exceptional cleaning equipment, a strong go-to-market strategy, and a differentiated customer support ecosystem. Brain Corp offers industry-leading and AI-enabled AMR cleaning technology, with more than 6,500 Tennant cleaning robots in the field powered by BrainOS®.

With this agreement and starting with the X4 ROVR, Tennant will begin offering an all-in-one AMR solution, with the equipment and autonomy services bundled as a single solution sold by Tennant. This new approach will simplify the buying experience for customers and result in Tennant benefiting from recurring revenue for autonomy services moving forward.

“This partnership further aligns two companies driven by a shared purpose: to elevate productivity and efficiency, and provide essential support for janitorial teams facing understaffing and overwhelming demand,” said Brain Corp CEO David Pinn. “At Brain Corp, we envision a world where people’s lives are made safer, easier, more productive, and more fulfilling with the help of robots, and I believe this expanded partnership will supercharge this into reality.”

“Innovation and customer focus are a significant part of Tennant’s identity,” said Huml. “This partnership amplifies our commitment to innovation as well as Brain Corp’s position as a pioneer in AI and automation applied to cleaning equipment. We are excited to unlock the full potential of next-generation robotic floor cleaning solutions that deliver true business value to customers who use our AMR equipment today and those who are waiting eagerly for an AMR solution that they can leverage for their businesses.”

With this agreement, Tennant invested $32 million in Brain Corp and Fay West, Tennant Company Senior Vice President and Chief Financial Officer, will join the Brain Corp board of directors.

About Tennant

Founded in 1870, Tennant Company (NYSE: TNC), headquartered in Eden Prairie, Minnesota, is a world leader in the design, manufacture and marketing of solutions that help create a cleaner, safer and healthier world. Its innovative products include equipment for maintaining surfaces in industrial, commercial and outdoor environments; detergent-free and other sustainable cleaning technologies; and cleaning tools and supplies. Tennant's global field service network is the most extensive in the industry. Tennant Company had sales of $1.24 billion in 2023 and has approximately 4,457 employees. Tennant has manufacturing operations throughout the world and sells products directly in 15 countries and through distributors in more than 100 countries. For more information, visit www.tennantco.com and www.ipcworldwide.com.

About Brain Corp

Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company's cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 30,000 AMRs, representing the largest fleet of its kind in the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222888342/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye